;

Auto Summaries - Drug
Last updated: 2024 Apr 18
Total hit(s): 6764
S.No.
1
38607273
The mouse to man conundrum: Revisiting an old lung injury model to study repurposed drugs for COVID-19 treatment.
N/A
Exp Physiol
2024 Apr 12
4.3
1
2
38511965
Erratum for Karaba et al., "Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment".
N/A
mBio
2024 Apr 10
6.5
1
3
38272241
N/A
2024 Apr
1
4
38335905
Convalescent plasma: An unexpected new therapeutic option for critically ill COVID-19 patients coming from the past.
N/A
J Clin Anesth
2024 Feb 8
2.74
1
5
38310906
Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2.
N/A
Lancet Infect Dis
2024 Feb 1
21.77
1
6
38048665
Fixation and reversion of mutations in the receptor-binding domain of SARS-CoV-2 spike protein.
N/A
Diagn Microbiol Infect Dis
2024 Feb
2.33
1
7
38297027
Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
N/A
Sci Rep
2024 Jan 31
4.12
1
8
36600579
N/A
2024 Jan 23
8
9
38219759
Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution.
N/A
Lancet Microbe
2024 Jan 11
- n/a -
1
10
38198126
When treatment takes a turn: tocilizumab-induced bowel perforation in a patient with COVID-19-afflicted rheumatoid arthritis.
N/A
Scand J Rheumatol
2024 Jan 10
1
11
38164631
The mutation point of view of the SARS-CoV-2 HV.1 lineage.
N/A
J Med Virol
2024 Jan
2.07
1
12
38149407
No emergence of resistance mutations in COVID-19 patients receiving nirmatrelvir/ritonavir.
N/A
J Med Virol
2024 Jan
2.07
1
13
38062689
[Expert consensus on diagnosis and treatment of severe COVID-19 associated with pulmonary aspergillus and mucormycosis].
N/A
Zhonghua Jie He He Hu Xi Za Zhi
2023 Dec 8
0.137 (5 year)
1
14
38070528
SARS-CoV-2 mucosal neutralising immunity after vaccination.
N/A
Lancet Infect Dis
2023 Dec 6
21.77
1
15
37074202
Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults.
mRNA-1283 is a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein. At the interim analysis, no safety concerns were identified and no serious adverse events, adverse events of special interest, or deaths were reported.
Hum Vaccin Immunother
2023 Dec 31
4.7
1
16
36846890
Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2.
The receptor-binding domain (RBD) of SARS-CoV-2 S protein is proved to be the major target of neutralizing antibodies. Only a portion of epitopes in RBD can be effectively displayed with dynamic changes in spatial conformations. Multimeric display of RBD molecules is a feasible strategy to optimize RBD-based vaccines.
Hum Vaccin Immunother
2023 Dec 31
4.7
1
17
38129796
Correction: Near complete genome sequences from Southern Vietnam revealed local features of genetic diversity and intergenerational changes in SARS- CoV-2 variants in 2020-2021.
N/A
BMC Infect Dis
2023 Dec 21
2.58
1
18
37272331
An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults.
The neutralizing activity of the human serum after Omicron-based vaccine booster against different SARS-CoV-2 variants is poorly understood. We developed a dose updated vaccine (SCoK-Omicron) based on the RBD-Fc fusion protein vaccine and RBD domain of Omicrons BA.1.1. Further assays of single point mutations showed that K444T, L452R, N460K, or F486V was key mutations to cause immune evasion.
Emerg Microbes Infect
2023 Dec
5.84
1
19
37408482
'Immune-inflammatory markers & clinical characteristics for outcomes in hospitalized SARS-CoV-2 infected patients of Pakistan: a retrospective analysis'.
Interleukin-6 (IL-6), Lactate dehydrogenase (LDH), C-reactive protein (CRP), Procalcitonin (PCT), ferritin and Complete blood count markers were measured. ROC analysis supports IL-6 as the most accurate marker with high prognostic relevance with proposed cut-off threshold (43 pg/ml)
Hematology
2023 Dec
- n/a -
1
20
36973648
In vitro studies of the renin-angiotensin system in human adipose tissue/adipocytes and possible relationship to SARS-CoV-2: a scoping review.
The renin-angiotensin system (RAS) operates within adipose tissue. Obesity-related changes can affect RAS, predisposing to hypertension, type 2 diabetes, and possibly severe COVID-19 infection. We evaluated the in vitro research on human adipose RAS and identified gaps in the literature.
Adipocyte
2023 Dec
1
21
36842064
Management of long-COVID-19 patients with sleep disorders: practical advice to general practitioners.
" According to the World Health Organization, GPs should be on the front line in the management of long-COVID-19 patients. The pieces advice presented in this correspondence are indispensable to resume the normal life of LC19Ps and promote their mental health recovery. Given the undesirable side effects associated with the use of hypnotics, the pharmacological approach must only be a ""last resort"""
Libyan J Med
2023 Dec
2.8
2
22
37154794
Antiviral and antibacterial potential of electrosprayed PVA/PLGA nanoparticles loaded with chlorogenic acid for the management of coronavirus and Pseudomonas aeruginosa lung infection.
Electrospraying technique was utilized to prepare CGA nanoparticles in polyvinyl alcohol (PVA/PLGA polymeric matrix) In vitro characterizations were performed to determine particle size, polydispersity index (PDI), zeta potential, loading efficiency (LE) and in vitro release study. The F2 exhibited antiviral activity against coronavirus (HCoV-229E) and MERS-CoV, NRCEHKU270.
Artif Cells Nanomed Biotechnol
2023 Dec
1
23
37186902
Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.
SARS-CoV-2 causes significant morbidity and mortality in humans. One factor that may influence virus control is pre-existing immunity conferred by an individual's past exposures to endemic coronaviruses (eCOVIDs) The nations where continuous exposures to eCOVIs are very high due to religious and traditional causes showed significantly lower cases and low mortality rates per 100,000.
Libyan J Med
2023 Dec
2.8
1
24
37144395
Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.
The main protease (3-chymotrypsin-like protease, 3CLpro) of SARS-CoV-2 has become a focus of anti-coronavirus research. Despite efforts, drug development targeting 3CLPro has been hampered by limitations in the currently available activity assays. Here, we report an orthogonal dual reporter-based gain-of-signal assay for measuring 3Clpro activity in living cells. This assay circumvents most limitations in previously reported assays, especially false positives caused by nonspecific compounds and signal interference from test compounds.
Emerg Microbes Infect
2023 Dec
5.84
1
25
36820816
The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection.
Anti-SARS-CoV-2S antibody levels were measured (ECLIA assay) in 50 healthcare workers with and without a history of COVID-19 infection to determine the humoral immune response to the third dose of the BNT162b2 vaccine. Age, gender, BMI, type work, type of work, and presence of comorbidities may be associated with different humoral immunizations. The results of this study can be used to improve the vaccination strategy for the general population.
Ann Med
2023 Dec
3.01
1